Navigation Links
PharmSource CMO-CDMO Database Expands Coverage to Include Approved Pharmaceutical Products: Intelligence Resource for Analyzing Bio/Pharmaceutical Contract Manufacturing
Date:7/16/2013

Fairfax, VA (PRWEB) July 16, 2013

The newest CMO-CDMO database offering from PharmSource is an upgrade to the widely respected PharmSource ADVANTAGE online service, and is a ready resource for deep insight into bio/pharmaceutical contract manufacturing trends based on key data that - until now - were difficult to find in a single, highly dependable source. New features in PharmSources' STRATEGIC ADVANTAGE online service include research capabilities to:

  •     Identify approved pharmaceutical products by CMO/manufacturer, applicant name or by product characteristics (including dosage form, route of administration, injectable packaging type, API, and more).
  •     Conduct searches for approved products by proprietary or generic product names, sponsor type, FDA and EU approvals, etc.
  •     Research pharmaceutical Merger & Acquisition activity by transaction nature, buyer or seller.
  •     Identify contract manufacturers by ownership type, including: government agency, not-for profit, private – management owned, private – venture capital owned, public company, unit of public company, university, etc. Search results include data on contract revenue ranges, when available.
  •     Download all search results into Excel, including side-by-side comparisons of contractor capabilities. This new feature is extremely valuable, as it allows users to freely use PharmSource Strategic Advantage data as part of their vital internal tool-kit for understanding the industry and trends.

PharmSource STRATEGIC ADVANTAGE service adds important support for sourcing and procurement executives who regularly make outsourcing decisions and assess contract manufacturing partners. It gives them an excellent resource for conducting high-level strategic analyses, including the ability to quickly and easily compare contract manufacturers, both in the detailed manufacturing capabilities they offer, and in their product experience.

Contract manufacturers also find great value in PharmSource STRATEGIC ADVANTAGE as a primary strategic planning and benchmarking resource to assess comparative capabilities, performance and product history. Just as important, it provides critical insight into likely future resource needs, identifying which pharmaceutical dosage forms have the greatest likelihood of being outsourced, and other critically important trends that drive major business decisions. It also is a resource for making trusted referrals.

For a limited time, a complimentary test-drive of PharmSource STRATEGIC ADVANTAGE is being offered to qualified companies. For more information, contact PharmSource's Customer Service Department at +1-703-383-4903, ext. 101 / info[at]pharmsource[dot]com.

About PharmSource

PharmSource brings together buyers and sellers of contract services for the development of drugs, medical devices and diagnostics. A trusted provider of global market and business intelligence since 1996, PharmSource publishes reports and databases, and conducts surveys and analyses related to industry contract service activities and trends.

Contact:
+1-703-383-4903 Phone (USA, eastern time-zone)
info(at)pharmsource(dot)com
http://www.pharmsource.com

Read the full story at http://www.prweb.com/releases/2013/7/prweb10468238.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmSource Lead Sheet Adds Coverage of Medical Devices and Diagnostics
2. Waters and NIBRT Complete Work on Worlds First UPLC Glycan Database
3. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
4. Elsevier Launches a New Product Literature Database Solution for Life Science Professionals
5. Conflict of Interest Management Tool Links with ProPublicas "Dollars for Docs" Database
6. ArteryHealth.org Launches as a Collective Database of Artery Health Research
7. WCCT Global (WCCT) & Verified Clinical Trials (VCT) Announce Medication Adherence Documentation Capabilities Have Been Added to the VCT Clinical Trials Database Registry
8. Verified Clinical Trials Will Exhibit at the Annual 2013 SCOPE Summit to Discuss the Professional Research Subject and the Clinical Trial Database Registry
9. ChemAxons Chemicalize.org Extends PubChem Database With Crowd-Sourced Chemistry From the Web
10. Verified Clinical Trials Exhibits at the Annual 2013 Partnerships In Clinical Trials to Discuss the Professional Research Subject and the Clinical Trial Database Registry
11. UV Flu Technologies Expands Its International Footprint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... SAN RAFAEL, Calif., Feb. 23, 2017 ... of U.S. dollars, except per share data, unaudited)Three Months ... ChangeTotal BioMarin Revenue $ ...     22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)...  Imanis Life Sciences announced today the launch ... viruses for virotherapy research. These viruses are licensed ... vaccinia virus-based technology platform for research use. ... partnership with Genelux to offer researchers, for the ... in research," said Dr. Kah Whye Peng ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... during the 12th annual Inventors Recognition Reception at Purdue Research Park ... a faculty member in recognition of outstanding contributions to, and success with, commercializing ...
Breaking Biology Technology:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
Breaking Biology News(10 mins):